Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Ipamorelin FDA Approved Status: Regulatory Comparison

Ipamorelin Not FDA-approved Phase I/II completed, no Phase III Investigational research compound GH secretion studies, body composition research Strongest evidence for selective GH release without cortisol/prolactin elevation. Lacks large-scale efficacy trials

This comparison does not assign a generated winner or score.

  • Ipamorelin
  • Not FDA-approved
  • Phase I/II completed, no Phase III
  • Investigational research compound
  • GH secretion studies, body composition research
  • Strongest evidence for selective GH release without cortisol/prolactin elevation. Lacks large-scale efficacy trials required for therapeutic approval
  • Sermorelin
  • FDA-approved (1997–discontinued 2008)
  • Phase III completed pre-approval
  • Previously approved, now unavailable
  • Historical GH deficiency treatment
  • Was FDA-approved for paediatric GH deficiency but withdrawn from market. Regulatory precedent exists but product unavailable
  • Tesamorelin
  • FDA-approved (2010)
  • Phase III completed
  • Prescription drug (Egrifta)
  • HIV-associated lipodystrophy
  • Only FDA-approved GHRH analogue currently marketed. Demonstrates full regulatory pathway peptides must complete
  • CJC-1295
  • Preclinical and Phase I only
  • Extended GH release research
  • Longer half-life than ipamorelin but minimal human clinical data. Regulatory status identical to ipamorelin
  • MK-677 (Ibutamoren)
  • Phase II completed for multiple indications
  • Sarcopenia, frailty, GH deficiency research
  • More extensive clinical evidence than ipamorelin but still lacks Phase III validation. Broader research adoption